尼罗替尼可诱导初诊慢性期慢性髓性白血病患者骨髓中CD34⁺/lin⁻Ph⁺细胞的早期清除。 - Suppr | 超能文献

Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia.

作者信息

Pungolino Ester, Rossi Giuseppe, De Canal Gabriella, Trojani Alessandra, D'adda Mariella, Perego Alessandra, Orlandi Ester Maria, Lunghi Francesca, Turrini Mauro, Borin Lorenza, Iurlo Alessandra, Latargia Maria Luisa, Carraro Maria Cristina, Spina Francesco, Lodola Milena, Artale Salvatore, Anghilieri Michela, Spedini Pierangelo, Cantoni Silvia, Di Camillo Barbara, Morra Enrica, Cairoli Roberto

机构信息

Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.

Department of Hematology, ASST Spedali Civili, Brescia, Italy.

出版信息

Am J Hematol. 2018 Jul;93(7):E162-E164. doi: 10.1002/ajh.25106. Epub 2018 May 17.

DOI:10.1002/ajh.25106

Abstract

摘要

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Nilotinib induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia.尼罗替尼可诱导初诊慢性期慢性髓性白血病患者骨髓中CD34⁺/lin⁻Ph⁺细胞的早期清除。

Am J Hematol. 2018 Jul;93(7):E162-E164. doi: 10.1002/ajh.25106. Epub 2018 May 17.

2

Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.尼罗替尼诱导初诊 CP 慢性髓性白血病骨髓 CD34+/lin-Ph+ 细胞早期清除：PhilosoPhi34 研究的最终报告。

Eur J Haematol. 2021 Oct;107(4):436-448. doi: 10.1111/ejh.13680. Epub 2021 Jul 6.

3

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.评价一线尼洛替尼治疗后达到完全细胞遗传学缓解的慢性髓性白血病患者体内残留的 CD34(+) Ph(+)祖细胞。

Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19.

4

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.新诊断的慢性髓性白血病患者中的白血病干细胞定量可预测尼洛替尼治疗的反应。

Clin Cancer Res. 2016 Aug 15;22(16):4030-8. doi: 10.1158/1078-0432.CCR-15-2791. Epub 2016 Mar 22.

5

Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.在接受酪氨酸激酶抑制剂治疗后处于完全细胞遗传学缓解期的慢性髓性白血病患者中，费城染色体阳性白血病干细胞（Ph(+)CD34(+)CD38(neg)）数量低或检测不到

Leukemia. 2010 Jan;24(1):219-22. doi: 10.1038/leu.2009.190. Epub 2009 Sep 24.

6

Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.慢性髓性白血病 CD34+ 细胞由于低 OCT-1 活性导致伊马替尼摄取减少。

Leukemia. 2010 Apr;24(4):765-70. doi: 10.1038/leu.2010.16. Epub 2010 Feb 11.

7

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.慢性髓性白血病干细胞区室的分子和功能分析显示，存在对伊马替尼具有内在耐药性的 CD34-细胞群。

Blood. 2009 Dec 10;114(25):5191-200. doi: 10.1182/blood-2008-08-176016.

8

Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.慢性髓性白血病干细胞具有多种独特的对BCR-ABL靶向治疗耐药的特征。

Leukemia. 2007 May;21(5):926-35. doi: 10.1038/sj.leu.2404609. Epub 2007 Mar 1.

9

[Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases].[接受BCR-ABL酪氨酸激酶抑制剂治疗的慢性髓性白血病患者骨髓中Ph阴性细胞的8号染色体三体性]

Ter Arkh. 2009;81(7):29-36.

10

Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.在慢性髓性白血病中进行“酪氨酸激酶抑制剂停药”之前，应在骨髓中寻找白血病干细胞。

Int J Lab Hematol. 2021 Oct;43(5):1110-1116. doi: 10.1111/ijlh.13528. Epub 2021 Apr 9.

引用本文的文献

1

Bone Marrow CD34+/lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects.尼洛替尼治疗12个月后慢性期慢性髓性白血病（CP-CML）患者的骨髓CD34+/lin-细胞与诊断时及健康受试者的相应细胞相比，表现出不同的基因表达特征。

Cancers (Basel). 2025 Mar 18;17(6):1022. doi: 10.3390/cancers17061022.

2

Occurrence of L1M Elements in Chromosomal Rearrangements Associated to Chronic Myeloid Leukemia (CML): Insights from Patient-Specific Breakpoints Characterization.L1M 元件在与慢性髓性白血病 (CML) 相关的染色体重排中的发生：来自患者特异性断点特征的见解。

Genes (Basel). 2023 Jun 27;14(7):1351. doi: 10.3390/genes14071351.

3

Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.尼罗替尼诱导初诊 CP 慢性髓性白血病骨髓 CD34+/lin-Ph+ 细胞早期清除：PhilosoPhi34 研究的最终报告。

Eur J Haematol. 2021 Oct;107(4):436-448. doi: 10.1111/ejh.13680. Epub 2021 Jul 6.

4

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.靶向慢性髓性白血病和费城染色体阴性经典骨髓增殖性肿瘤中的异常造血干细胞

Int J Mol Sci. 2021 Jan 11;22(2):659. doi: 10.3390/ijms22020659.

5

Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment.尼洛替尼治疗 12 个月后可干预慢性期慢性髓性白血病患者 CD34+/lin- 细胞的细胞周期、ABC 转运蛋白和 JAK-STAT 信号通路。

PLoS One. 2019 Jul 18;14(7):e0218444. doi: 10.1371/journal.pone.0218444. eCollection 2019.